Multi-dimensional C19 treatment model of the McCullough protocol – showing the applicability of different treatments for each stage and severity – along with detailed statistical proofs
From this 111 minute here:
Ivermectin as a key component in a protocol that cures hypoxemia! The key point is that no one element will work – a multi-faceted treatment protocol is needed that depends on the individual circumstances of the patient (definitely NOT one-size fits all) and the stage of the disease.
Here is an illustration of the temporal aspects and treatments.
Lots of analysis of Hypoxemia = short internet description - long version in the presentation
“Hypoxemia is a below-normal level of oxygen in your blood, specifically in the arteries. Hypoxemia is a sign of a problem related to breathing or circulation, and may result in various symptoms, such as shortness of breath.”
And the alveoli@ - short description:
“Gas exchange takes place in the millions of alveoli in the lungs and the capillaries that envelop them. … inhaled oxygen moves from the alveoli to the blood in the capillaries, and carbon dioxide moves from the blood in the capillaries to the air in the alveoli.”
There is so much depth and detail it is difficult to summarize. Suffice to say, it is an in-depth presentation and one for the Professors of numbers to enjoy!
I think, though may be mistaken, that much of the comparative analyses refer to this:
The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease - PMC (nih.gov)
What caught my eye was this table for the (mostly?) Beta variant
Look at the hospitalized case fatality rate – MORE THAN 20%!!! For the beta variant.
Could it be that doing nothing was better than the treatment protocols used AND that treatment protocols did far, far better?
Not making any claims about voracity of these studies compared to any other studies, but here are a couple of papers on the case fatality rate from first the Beta variant, the Alpha. I think that the Africa studies were done covering both Alpha and Beta variant dominant periods.
Makes you wonder how many in the studies had previously been treated with Ivermectin in the sub-Saharan countries f Zimbabwe and Suth Africa compared to those I West Africa in countries like Nigeria – both within the sub-Saharan country studies and across the Adria continent!
“Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.”
Beta variant was 2.6 times the Alpha variant.
From here.
“The impact of Alpha variant on mortality seems to depend on the patient's age. For patients under age of 70, the case-fatality-rate was 0.84% (5.3%) for patients without (with) Alpha variant (Fisher's test P-value = 2.4 × 10-10). For patients above age of 70, the trend is opposite: the case-fatality-rate is 31.5% (13.6%) for patients without (with) Alpha variant (Fisher's test P-value = 0.0016).”
"Under 70’s 0.85%, over 70’s 40.5% for Alpha.
This led me to think that it is not the disease itself or the infection - that needs to be highlighted – but the disease/infection PLUS the treatment that needs considering. After all, we know the cure via the FAILED experimental modified mRNA injections with all their contaminants and adulterations are more toxic than C19!
Onwards!!!
Please subscribe ten dollars a month or annually for 100 bucks. You can also donate via Ko-fi – any amount from three dollars upwards. Ko-fi donations here: https://ko-fi.com/peterhalligan